Aeterna Zentaris Inc. (AEZS, AEZ.TO) said it and Keryx Biopharmaceuticals, Inc. (KERX) have agreed to terminate their license agreement with respect to perifosine, as a result of which Aeterna Zentaris has regained in full the North American rights to its Akt inhibitor anticancer compound, perifosine, in all indications. Termination of the agreement was effective as of May 4, 2012.
The company also said it will continue the ongoing Phase 3 trial in multiple myeloma with this compound.
As per the terms of the agreement to terminate, all intellectual property and development data, including orphan drug designations and Investigational New Drug applications on perifosine generated by Keryx, have been transferred to Aeterna Zentaris. In return, Aeterna Zentaris has agreed to pay low single-digit royalties to Keryx on future net sales of perifosine in North America.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.